Cytarabine and Daunorubicin

Therapeutic indications

Cytarabine and Daunorubicin is indicated for:

Acute myeloid leukaemia

Population group: only adults (18 years old or older)

Daunorubicin/cytarabine combination is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

44 mg/m² of daunorubicin and 100 mg/m² of cytarabine during first and second induction and 29 mg/m² of daunorubicin and 65 mg/m² of cytarabine during the consolidation

Contraindications

Cytarabine and Daunorubicin is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.